SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil Corp ($BATL) is experiencing a massive rally, fueled by reports of Iran threatening or closing the Strait of Hormuz, leading to anticipation of surging oil prices. The low-float energy stock is seeing intense community discussion around a potential short squeeze, driven by extremely high borrow fees and expectations of reaching $20-$50+.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending amid surging interest in photonics solutions for AI data centers, buoyed by recent institutional investment, a strategic partnership mention from Quantum Computing, and NVIDIA's broader sector validation. The community is actively discussing POET's optical interposer technology as a key enabler for next-generation high-speed interconnects and eagerly awaits major customer announcements.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd (INDO) is trending as the Middle East conflict escalates, with reports of the Strait of Hormuz closure fueling expectations of soaring oil prices, though the community is actively discussing why INDO isn't matching the significant runs seen in peer oil stocks like BATL.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in November 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB is trending following a significant stock drop, driven by cautious short-term guidance and recent leadership transitions, despite strong past earnings. This has ignited community debate, with some citing broader software sector pressures and growth concerns, while others see it as an exaggerated sell-off presenting a long-term buying opportunity given its AI and database platform.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following a positive earnings call that included accelerating satellite deployment plans, optimistic revenue growth guidance, and new partnerships with global telecom providers. The community is actively discussing the company's full funding for its constellation, expected additional announcements, and its emerging role in defense and space-based AI, prompting strong bullish sentiment against persistent skepticism.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending as the first eVTOL company to achieve 100% FAA Means of Compliance acceptance, a pivotal regulatory milestone that bulls believe significantly de-risks its path to 2026 piloted operations, while community discussion continues around its Q4 loss and ongoing capital requirements.

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work. The UnCrewed Systems segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence, and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is trending after a significant sell-off, driven by a Raymond James downgrade citing the recompeting of a $1.4 billion Space Force contract. Yet, many in the community perceive this as an overreaction and a buying opportunity, emphasizing other bullish analyst targets and robust demand for drones amid global conflicts.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending amid escalating geopolitical tensions driving increased demand for drone and autonomous defense solutions, with the community actively discussing potential short squeeze opportunities fueled by high volume and optimistic contract prospects.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is trending following its full-year 2025 earnings, which reported record revenue exceeding $100 million and significant profitability improvements, fueling community debate over its perceived undervaluation and ambitious $7B+ AI infrastructure pipeline, while skeptics point to past execution concerns and low institutional ownership.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group (DJT) is trending due to the Trump administration's ongoing military strikes against Iran, which has ignited polarized community discussions. While proponents hail the actions as vital for global security, critics widely dismiss it as an "illegal war" and a distraction from domestic issues and the "Epstein files," fueling intense debate and contributing to the stock's volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tonix Pharmaceuticals (NASDAQ:TNXP) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday...

Tonix Pharmaceuticals (NASDAQ:TNXP) Cut to "Sell" at Wall Street Zen

Wall Street Zen downgraded Tonix Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday...

<ul class="summary-bullets"><li>Tonix intends to advance TNX-4800 with the goal of submitting an application to the FDA seeking approval to market it.</li><li>The company licensed TNX-4800 from its developers at UMass Chan Medical School in September.</li><li>There are currently no FDA-approved vaccines or preventive medicines to protect against Lyme disease.</li></ul>Tonix Pharmaceuticals Holding Corp. (TNXP) announced on Monday that it intends to meet with the U.S. Food and Drug Administration in 2026 to discuss the development of its experimental drug in the treatment of Lyme disease.The company licensed TNX-4800 from its developers at UMass Chan Medical School in September. It is being developed for annual seasonal use, as one subcutaneous administration in the spring to protect against Lyme disease through fall, or the entire tick season in the U.S., without relying on the recipient’s immune system to generate antibodies.<h2 class="st-heading-2">What Is Lyme Disease?</h2>Lyme disease is a bacterial infection caused by the bacterium Borrelia burgdorferi and spread by infected blacklegged ticks. It causes symptoms such as a bull's-eye rash, fever, fatigue, and headaches, and, if untreated, can spread to joints, heart, and brain.There are currently no FDA-approved vaccines or preventive medicines to protect against Lyme disease. According to Tonix, it is the most common vector-borne infection in the United States, and its incidence is climbing each year.<h2 class="st-heading-2">Tonix Eyes Advancing The Drug</h2>Tonix intends to advance TNX-4800 with the goal of submitting an application to the FDA seeking approval to market it.“We believe a controlled human infection model (CHIM)3-5 study using Borrelia-infected ticks that mimics natural infection would be a potential path to demonstrating TNX-4800 efficacy for approval,” <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tonixpharma.com/news-events/press-releases/detail/1606/tonix-pharmaceuticals-announces-program-updates-on-phase">said</a> CEO Seth Lederman. He added that the firm expects to have the investigational product ready for clinical trials by early 2027.<h2 class="st-heading-2">Registered Direct Offering</h2>Separately, the company also announced the pricing of a $20.0 million registered direct offering on Monday<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tonixpharma.com/news-events/press-releases/detail/1607/tonix-pharmaceuticals-announces-pricing-of-20-0-million"> at about</a> $16.26 per share/warrant. &nbsp;The firm intends to use the net proceeds from the offering to fund the commercialization of its marketed products, the development of its product pipeline, and general working capital and corporate purposes.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TNXP stayed within the ‘bearish’ territory while message volume stayed at ‘low’ levels.A Stocktwits user sounded optimistic about the stock.<stembedurl>https://www.stocktwits.com/ZenofWealth/message/640294827</stembedurl><a href="https://stocktwits.com/symbol/TNXP">TNXP stock</a> is down 51% this year and by about 55% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nasa-administrator-jared-isaacman-sees-us-return-to-moon-before-trump-presidential-term-expiry/cLeCD4iREDB">NASA Administrator Jared Isaacman Sees US Return To Moon Before Trump’s Presidential Term Expiry</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Tonix Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Tonix Pharmaceuticals To Meet With FDA In 2026 To Advance Experimental Lyme Disease Prevention Drug

The company also announced the pricing of a $20 million registered direct offering. 

Equity

The company also announced the pricing of a $20 million registered direct offering. 


Noble Financial Has Positive Outlook of TNXP FY2025 Earnings

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Investment analysts at Noble Financial raised their FY2025 earnings per share estimates for shares of Tonix Pharmaceuticals in a...

Equities Analysts Offer Predictions for TNXP FY2025 Earnings

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) - Equities research analysts at Zacks Small Cap raised their FY2025 earnings per share estimates for Tonix Pharmaceuticals in a report...

<ul class="summary-bullets"><li>Retail traders pointed to the expanded buyback authorization as a sign of management confidence, framing it as a potential catalyst for renewed valuation upside.</li><li>The commercial rollout of Tonmya and buyback progress strengthened bullish sentiment around the company’s turnaround.</li><li>Some users speculated that the larger repurchase program could pressure short sellers or even hint at early buyout interest.</li></ul>Tonix Pharmaceuticals stock moved into sharp retail focus on Tuesday after the company expanded its share repurchase authorization by an additional $25 million, bringing the total buyback capacity to $35 million. The move came just one day after Tonix launched Tonmya, its newly approved fibromyalgia treatment, into U.S. pharmacies.<h2 class="st-heading-2">Buyback Expansion Sparks Bullish Retail Reaction</h2>On Stocktwits, retail sentiment for Tonix was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:970/148;" src="https://news.stocktwits-cdn.com/tnxp_ss_png_226c90b15a.webp" alt="tnxp ss.png" width="970" height="148"><figcaption>TNXP sentiment and message volume as of November 18 | Source: Stocktwits</figcaption></figure>In an 8-K filing on Tuesday, the company approved the increased buyback authorization, a signal retail traders interpreted as management showing confidence in Tonix’s valuation. One user said the upbeat tone of the filing, combined with clear progress on the Tonmya rollout, created a “blueprint for a rerating,” adding that companies don’t authorize larger repurchases unless they believe the stock is undervalued.<stembedurl>https://stocktwits.com/Doyoubelieveit/message/636681899</stembedurl>Another user highlighted Tonix’s turnaround, noting that investors who bought shares before FDA approval and commercialization were taking on significantly more risk. “we now have a FDA approved product, more cash than MCAP, huge pipeline, commercialization, grants, fast track designation, increased share buyback and many more,” the user said.<stembedurl>https://stocktwits.com/StockJayC/message/636677513</stembedurl><h2 class="st-heading-2">Short-Squeeze And Buyout Speculation Emerges</h2>The buyback news also triggered speculation about pressure on short sellers. One retail trader suggested that repurchases could force shorts to compete for shares, saying the company’s decision signaled it was “done with ATM dilution.”&nbsp;Another argued the enlarged buyback could “equal huge short squeeze,” while a separate user linked the authorization to potential M&amp;A interest, saying a repurchase program “makes sense if you’re being contacted about a buyout.”<stembedurl>https://stocktwits.com/TrendSetter67/message/636675726</stembedurl><stembedurl>https://stocktwits.com/shockfactor/message/636675727</stembedurl><stembedurl>https://stocktwits.com/Ripcurlinvestments/message/636677437</stembedurl><h2 class="st-heading-2">Tonmya Launch Adds Momentum</h2>Tonix&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-tnxp-stock-jump-10-today/cLPlTiTREef">began commercial distribution of Tonmya&nbsp;</a>on Monday, a prescription, non-opioid bedtime tablet approved for treating fibromyalgia in adults. The company said the drug is now available in U.S. pharmacies, calling the launch a “momentous day” for the estimated 10 million Americans living with fibromyalgia.The treatment received FDA approval in August based on two Phase 3 trials involving nearly 1,000 patients, which demonstrated reductions in daily pain and improvements in sleep, fatigue and overall functioning over 14 weeks. Side effects were mostly mild, including drowsiness, dry mouth and temporary oral numbness.<a href="https://stocktwits.com/symbol/TNXP">Tonix’s stock</a> has slumped 51% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tonix Pharmaceuticals Stock Jumps Into Retail Spotlight After $25M Buyback Boost — Traders See ‘Blueprint For Rerating’

Retail traders pointed to the expanded buyback authorization as a sign of management confidence, framing it as a potential catalyst for renewed valuation upside.

<ul class="summary-bullets"><li>Tonmya’s FDA approval on Aug. 15, 2025, was based on results from two Phase 3 studies involving nearly 1,000 patients.</li><li>The most common side effects included mild mouth numbness or discomfort, altered taste, drowsiness, fatigue, dry mouth, and canker sores.</li><li>TNXP was among the top trending tickers on Stocktwits on Monday morning.</li></ul>&nbsp;Shares of Tonix Pharmaceuticals (TNXP) surged 10% on Monday after the company announced the launch of its new drug to treat Fibromyalgia.&nbsp;TNXP was among the top trending tickers on Stocktwits on Monday morning following the announcement. Tonix’s Tonmya is a prescription drug for the treatment of Fibromyalgia in adults. The company said that the non-opioid tablet, which can be taken once at bedtime, is now available in U.S. pharmacies.Fibromyalgia is a condition that causes widespread muscle and joint pain, often accompanied by fatigue. Its exact cause is unknown, but studies suggest that stress can play a role in triggering the symptoms.“The availability of Tonmya is a momentous day for Tonix, providing the estimated 10 million people living with fibromyalgia a novel treatment that has been shown to address the debilitating, core symptom of this disease, widespread pain,” said Seth Lederman, CEO of Tonix Pharmaceuticals.<h2 class="st-heading-2">Tonmya Trials</h2>Tonmya’s FDA approval on Aug. 15, 2025, was based on results from two Phase 3 studies involving nearly 1,000 patients, in which the drug showed meaningful reductions in daily pain over 14 weeks compared with placebo.A higher share of patients on Tonmya also achieved at least a 30% improvement in pain after three months. Findings from the RESILIENT Phase 3 trial highlighted improvements in symptoms, including sleep issues, fatigue, and overall patient functioning.The most common side effects included mild mouth numbness or discomfort, altered taste, drowsiness, fatigue, dry mouth, and canker sores.<h2 class="st-heading-2">What Are Stocktwits Users Saying?</h2>Retail sentiment on Stocktwits remained in the ‘bullish’ territory over the past 24 hours, accompanied by ‘high’ message volumes. One Stocktwits user believes there is a potential for further upside before the market closes on Wednesday.<stembedurl>https://stocktwits.com/alecsalaur198/message/636442989</stembedurl>Another user believes the stock has long-term potential.<stembedurl>https://stocktwits.com/YourAverageStockGuy/message/636441761</stembedurl>TNXP shares have shed nearly half their value so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did TNXP Stock Jump 10% Today?

Tonix Pharmaceuticals on Monday announced the launch of its new drug to treat Fibromyalgia.

Tonix Pharmaceuticals (NASDAQ:TNXP) Announces Quarterly Earnings Results

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) released its quarterly earnings results on Monday. The company reported ($3.59) earnings per share (EPS) for the quarter, hitting the consensus...

Shares of Tonix Pharmaceuticals Holding Corp. (TNXP) jumped 4% in the pre-market session on Monday after its drug Tonmya received the U.S. Food and Drug Administration’s (FDA) approval for the treatment of fibromyalgia in adults.Fibromyalgia is a chronic pain disorder that is understood to result from amplified sensory and pain signaling within the central nervous system. Fibromyalgia afflicts an estimated 10 million adults in the U.S., mostly women, and symptoms include chronic widespread pain and fatigue, among others.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tonixpharma.com/news-events/press-releases/detail/1585/tonix-pharmaceuticals-announces-fda-approval-of">announced</a> the approval on Friday evening. Tonmya is a non-opioid, once-daily bedtime analgesic designed for rapid absorption into the bloodstream. It is also the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years, Tonix said.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TNXP">Tonix</a> trended in the ‘extremely bullish’ territory over the past 24 hours, coupled with ‘extremely high’ message volume. According to Stocktwits data, retail chatter around the stock jumped 72% over the past 24 hours and by 281% over the past seven days.<figure class="image"><img style="aspect-ratio:566/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_18_at_8_26_39_AM_png_c112eeec38.webp" alt="TNXP's Sentiment Meter and Message Volume as of 8:25 a.m. ET on Aug. 18, 2025 | Source: Stocktwits" width="566" height="62"><figcaption>TNXP's Sentiment Meter and Message Volume as of 8:25 a.m. ET on Aug. 18, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user dismissed hopes for a massive rally, adding that ‘this is a marathon not a sprint.’<stembedurl>https://stocktwits.com/AlwaysABullNeverABear/message/625581652</stembedurl>Another user said they see significant market potential for the drug.<stembedurl>https://stocktwits.com/GeneralAdam/message/625580421</stembedurl>In two late-stage trials, Tonmya significantly reduced fibromyalgia pain compared to placebo at 14 weeks. The drug was generally well-tolerated in late-stage trials, and a greater percentage of study participants taking Tonmya experienced a clinically meaningful improvement in their pain after three months, compared to placebo. Tonmya is expected to be available for adult patients in the U.S. with fibromyalgia beginning in the fourth quarter of this year.TNXP stock is up by 56% this year and by over 15% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-slips-under-116000-while-cardano-solana-lead-altcoin-selloff/chsO7iYRdQw">Bitcoin Slips Under $116,000 While Cardano, Solana Lead Altcoin Selloff</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Pharma Stock Shot Up 4% Pre-Market After FDA Approval For Drug, Retail’s Super Bullish But Believes ‘This Is A Marathon, Not A Sprint’

Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years, Tonix said. 

Tonix Pharmaceuticals drew heavy retail chatter on Tuesday ahead of an expected U.S. Food and Drug Administration decision on its experimental fibromyalgia treatment TNX-102 SL, due&nbsp;Friday.If approved, the drug would be the first new treatment for fibromyalgia in more than 16 years. It’s taken as two 2.8 mg tablets placed under the tongue before bed.&nbsp;<a href="https://stocktwits.com/symbol/TNXP">Tonix Pharma’s stock</a> jumped 32.9% to $14.79 on Tuesday, its best session in nearly five months, before edging up another 0.23% in after-hours trading.The centrally acting, non-opioid analgesic is designed for rapid transmucosal absorption, avoiding first-pass metabolism and reducing levels of a long half-life metabolite.The treatment earned Fast Track status from the FDA last year. In the late-stage RESILIENT trial, which enrolled 457 patients across 33 U.S. sites, those on TNX-102 SL reported a bigger drop in daily pain scores over 14 weeks compared with placebo, marking a 1.8-point reduction versus 1.2.&nbsp;It met all six secondary endpoints, and it's effective for sleep, fatigue, and general functioning. Side effects were mild, temporary, and generally limited to a tingling in the mouth or a bitter aftertaste. There were no serious drug-related adverse events.Tonix expects to roll out the treatment in the fourth quarter if it receives the green light, and stated that patents should protect U.S. sales until 2034-2035. The company is also testing the drug for other uses, including acute stress reaction, prevention of PTSD, Long COVID, alcohol use disorder, and agitation linked to Alzheimer’s disease.The rest of Tonix’s pipeline includes a Defense Department–backed study of TNX-102 SL for acute stress reaction, an anti-CD40L antibody called TNX-1500 aimed at preventing organ transplant rejection, and TNX-801, a live-virus vaccine candidate for mpox and smallpox.As of June 30, Tonix had $125.3 million in cash, plus additional funds from recent stock sales, which it stated will sustain operations through the third quarter of 2026.&nbsp;In the latest quarter, net revenue&nbsp;totaled $2 million, primarily from migraine drugs, while its net loss narrowed to $28.3 million from $78.8 million in the same period a year earlier.&nbsp;The company also launched its Move Fibro Forward campaign to raise awareness for fibromyalgia, a condition that affects millions of Americans and has long had limited treatment options.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 222% surge in 24-hour message volume, making it one of the platform’s top four trending equities.One user commented that $TNXP had delivered sixfold gains in six months, citing the second-quarter earnings beat and the upcoming FDA decision as reasons they considered it a “keeper.”<stembedurl>https://stocktwits.com/CCTVon/message/624881071</stembedurl>Another user remarked that despite past losses in the stock, the Fast Track status, lack of an advisory committee, and two strong Phase 3 results made the August 15 decision look promising.<stembedurl>https://stocktwits.com/SIRWINSALOT/message/624885454</stembedurl>Tonix Pharma’s stock has risen 81.2% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tonix Pharmaceuticals (TNXP) drew heavy retail chatter on Tuesday ahead of an expected U.S. Food and Drug Administration decision on its experimental fibromyalgia treatment TNX-102 SL, due Friday. (Photo credit: Getty Images)

Tonix Pharma Scores Best Day Since March On Hopes For First New Fibromyalgia Drug Approval in 16 Years; Retail’s Optimistic

The late-stage candidate TNX-102 SL has received FDA Fast Track status and has delivered positive results in two pivotal Phase 3 trials, demonstrating meaningful pain reduction.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $MDB earnings today?

Current Price	$13.98
Prev Close	$13.97
Open	$13.34
Dividend Yield	0.00%
50-Day Moving Average	$16.31
Beta	1.23
Avg. Volume	457,657.90
PE Ratio	-0.01

52-Week High	$69.97
52-Week Low	$6.76
Market Capitalization	$178.65M
EPS (Annual)	-$17,659.80
Price to Book	0.61
Revenue Per Employee	$124,617.28

TNXP
Tonix Pharmaceuticals Holding Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TNXP News

TNXPTonix Pharmaceuticals Holding Corp